Similarly to previous experiments, we observed in the H358 model that although the tumors treated with single-targeting KRAS and MYC siRNAs showed disease control in comparison with the control-treated group within a week, the rate of tumor growth was much more effectively inhibited following treatment with the MYC/KRAS chimeric siRNA (Figure 9A and Supplemental Figure 15A). This evidence concerns the gene KRAS and neoplasm.